Current Status and Prospect of Delivery Vehicle Based on Mesenchymal Stem Cell-Derived Exosomes in Liver Diseases
DOI: https://doi.org/10.2147/IJN.S404925
IF: 7.033
2023-05-31
International Journal of Nanomedicine
Abstract:Xinfeng Lu, 1, 2, &ast Haijun Guo, 2, 3, &ast Xuyong Wei, 2, 3 Di Lu, 2, 3 Wenzhi Shu, 2, 4 Yisu Song, 2, 4 Nasha Qiu, 1, 2 Xiao Xu 1– 4 1 The Fourth School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, 310000, People's Republic of China; 2 Key Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province, Hangzhou, 310006, People's Republic of China; 3 Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, 310006, People's Republic of China; 4 Zhejiang University School of Medicine, Hangzhou, 310058, People's Republic of China &astThese authors contributed equally to this work Correspondence: Xiao Xu, Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, 310006, People's Republic of China, Email Nasha Qiu, The Fourth School of Clinical Medicine, Zhejiang Chinese Medical University, Key Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province, Hangzhou, 310006, People's Republic of China, Email With the improvement of the average life expectancy and increasing incidence of obesity, the burden of liver disease is increasing. Liver disease is a serious threat to human health. Currently, liver transplantation is the only effective treatment for end-stage liver disease. However, liver transplantation still faces unavoidable difficulties. Mesenchymal stem cells (MSCs) can be used as an alternative therapy for liver disease, especially liver cirrhosis, liver failure, and liver transplantation complications. However, MSCs may have potential tumorigenic effects. Exosomes derived from MSCs (MSC-Exos), as the important intercellular communication mode of MSCs, contain various proteins, nucleic acids, and DNA. MSC-Exos can be used as a delivery system to treat liver diseases through immune regulation, apoptosis inhibition, regeneration promotion, drug delivery, and other ways. Good histocompatibility and material exchangeability make MSC-Exos a new treatment for liver diseases. This review summarizes the latest research on MSC-Exos as delivery vehicles in different liver diseases, including liver injury, liver failure, liver fibrosis, hepatocellular carcinoma (HCC), and ischemia and reperfusion injury. In addition, we discuss the advantages, disadvantages, and clinical application prospects of MSC-Exos-based delivery vectors in the treatment of liver diseases. Keywords: exosomes, mesenchymal stem cells, liver disease, nanocarriers The WHO identified that the world's overweight and obesity rates have nearly tripled since 1975. By estimation, more than 1.9 billion (39%) adults (≥18 years) are overweight and 650 million (13%) individuals are obese. 1 With the improvement of the average life expectancy and increasing incidence of obesity, the burden of various liver diseases, including non-alcoholic fatty cell liver disease (NAFLD), liver cirrhosis, and liver failure, is increasing. 2 These high rates of morbidity pose a great threat to human health. 3 Chronic liver disease and cirrhosis contribute to 2 million deaths per year globally, with a high burden of disability and treatment costs. 4,5 The prevalence of alcoholic liver disease and NAFLD in the general adult population is approximately 7.4% and 20–33%, respectively. Hepatitis B virus (HBV) infection affects at least 2 billion people worldwide, and without radical treatment, all forms of chronic hepatitis eventually progress to end-stage disease. Hepatocellular carcinoma (HCC) was reported to be the leading cause of cancer death worldwide. 6 Liver cancer is the fourth leading cause of cancer-related death worldwide and the second most lethal cancer with a 5-year survival rate of 18%. 7,8 In 2030, the WHO estimates that more than 1 million patients will die from liver cancer. 8 The liver disease accounts for about 2 million deaths worldwide every year, 9 which poses a great threat to human health. Liver transplantation is the only effective treatment for many advanced liver diseases when other medical therapies have failed. 10–12 However, we have to admit that the shortage of liver donors, high cost, postoperative complications, and other issues restrict the popularization of liver transplantation. Therefore, we hope to find effective alternative measures to cope with the occurrence and development of liver diseases. MSC-Exos can inhibit the occurrence and development of liver injury, liver fibrosi -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology